Navigation Links
N30 Pharma Announces License Agreement With NitroMed, Inc.
Date:10/29/2007

BOULDER, Colo., Oct. 29 /PRNewswire/ - N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of respiratory drugs that target endogenous s-nitrosothiols, today announced a licensing agreement with NitroMed Inc. (Nasdaq: NTMD) covering the respiratory use of a s-nitrosothiol drug candidate. Financial terms of the deal were not disclosed.

"I am extremely pleased to announce this agreement. NitroMed is a leader in exploring the medical utility of Nitric Oxide and s-nitrosothiol therapies, and has foundational intellectual property in the area," commented Charles Scoggin, M.D., Chairman of N30 Pharma.

N30 Pharma is developing s-nitrosothiol therapies for critical unmet needs in important respiratory diseases such as cystic fibrosis (CF), asthma, and chronic obstructive pulmonary disease (COPD). S-nitrosothiols are endogenous molecules that store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone, as well as having other effects. N30 is a privately held company headquartered in Boulder, Colorado.


'/>"/>
SOURCE N30 Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... IN (PRWEB) May 28, 2015 The Academy ... National Model Aviation Day on August 15, 2015. National Model ... aviation nation-wide and to introduce model flying to the general ... 2,350 chartered clubs to participate in the celebration by hosting ... registered to host National Model Aviation Day events. View ...
(Date:5/28/2015)... May 28, 2015 DryLet, LLC ... in applications such as animal waste reduction, bioremediation, ... reduction in wastewater treatment plants and restaurant kitchen ... World Pork Expo, June 3-5 in Des Moines, ... in a Wall Street Journal article because of ...
(Date:5/28/2015)... RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... therapeutics, primarily in the areas of dermatology and ophthalmology, ... 26 million units at a price to the public ... $10.4 million. Each unit consists of (i) one share ... to purchase 0.50 of a share of common stock ...
(Date:5/28/2015)... and London (PRWEB) May 28, 2015 ... of Computer Aided Engineering software, announced today it ... Inc. (PSRI). CD-adapco will provide state-of-the-art engineering simulation ... will share their expertise and experiences in analyzing ... refining industry members and advance the understanding of ...
Breaking Biology Technology:Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2DryLet to Showcase Patented ManureMagic™ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... be made using molybdenite. In an article appearing online ... EPFL,s Laboratory of Nanoscale Electronics and Structures (LANES) publishes ... over traditional silicon or graphene for use in electronics ... an important role in electronics, allowing us to make ...
... 28, 2011 Neuralstem, Inc. (Amex: CUR ... ReNeuron, Ltd. ending litigation between the parties.  The confidential ... ReNeuron in Neuralstem, Inc. v. ReNeuron, Ltd. , ... in the United States District Court for the Central ...
... available in Spanish and French . , ... From this fibrous diet consisting mainly of the tough to degrade ... value to most animals, ruminants manage to extract all they need ... now, the cow, or rather the network of organisms working unseen ...
Cached Biology Technology:New transistors: An alternative to silicon and better than graphene 2Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd. 2How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 2How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 3How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 4How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 5
(Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
(Date:5/18/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... July 15, 2013 Dr. Jeffrey Trent, President and ... will discuss state-of-the-art genomics research July 16 at the ... former Scientific Director of the National Human Genome Research ... at Brookings, 2nd annual State of Biomedical Innovation Conference, ...
... Ice Age, as the world began to warm, a swath ... brief pulse of biological productivity 14,000 years ago, this stretch ... tiny creatures, who thrived in large numbers until the productivity ... Researchers have hypothesized that iron sparked this surge ...
... by slugs may prevent key grassland species from taking ... new research has shown., Work by scientists at Newcastle ... on grassland biodiversity and how this might inform future ... through a gardener,s prize petunias or strawberry patch, still ...
Cached Biology News:TGen President Dr. Jeffrey Trent speaks at Brookings Institution biomedical conference 2Scientists solve a 14,000-year-old ocean mystery 2Scientists solve a 14,000-year-old ocean mystery 3Grazing slugs hinder grassland restoration 2
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
APOPTAG® Plastic Coverslips are designed to be custom fitted to the specific APOPTAG® kit application. Each coverslip has 2.5 x 1 dimensions....
Human VEGF-D Biotinylated MAb (Clone 78923)...
Biology Products: